Skip to content
DataLookout
Menu

NCT06471543

Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects

StatusCompleted
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 24 words Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 2 entries
    • Trial completed
    • Study completion date changed from estimate of Aug 26, 2026 to Aug 25, 2026
    • Secondary endpoints: details revised at 12 of 15 entries
    • Site details revised at 2 of 10 sites
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 9 to 10
    • Primary completion date: Sep 30, 2026 to Jun 3, 2026
    • Study completion date: Dec 30, 2026 to Aug 26, 2026
    v4
  3. Notable Phase: Phase 1 to Phase 1/2v2 Show 9 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Enrollment target: 60 to 108
    • Primary completion date: Sep 30, 2025 to Sep 30, 2026
    • Eligibility criteria expanded, about 167 words
    • Primary endpoints: 6 to 2
    • Study sites: 1 to 9
    • Study completion date: Jun 30, 2026 to Dec 30, 2026
    • Secondary endpoints: 12 to 15
    • Study title expanded, about 4 words
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number and incidence of adverse events (AEs)/serious adverse events (SAEs) possibly or probably related to treatment of RN0361 in adult healthy subjects.
Timeframe: Up to Day85
Absolute and percent change from baseline in APOC3 and fasting triglycerides (TG) in subjects with HTG
Timeframe: Up to Day183

Secondary (15)

Plasma pharmacokinetics (PK) parameters (Cmax) of a single ascending SC dose of RN0361 and its metabolite AS3'N-1 in adult healthy subjects.
Plasma pharmacokinetics (PK) parameters (Tmax) of a single ascending SC dose of RN0361 and its metabolite AS3'N-1 in adult healthy subjects.
Plasma pharmacokinetics (PK) parameters (AUC 0-24) of a single ascending SC dose of RN0361 and its metabolite AS3'N-1 in adult healthy subjects.
Plasma pharmacokinetics (PK) parameters (t1/2) of a single ascending SC dose of RN0361 and its metabolite AS3'N-1 in adult healthy subjects.
Plasma pharmacokinetics (PK) parameters (AUC0-inf) of a single ascending SC dose of RN0361 and its metabolite AS3'N-1 in adult healthy subjects.
Show 10 moreShow less
Plasma pharmacokinetics (PK) parameters (Vz/F) of a single ascending SC dose of RN0361 and its metabolite AS3'N-1 in adult healthy subjects.
Plasma pharmacokinetics (PK) parameters (λz) of a single ascending SC dose of RN0361 and its metabolite AS3'N-1 in adult healthy subjects.
Urine pharmacokinetics (PK) parameters (CLR) of a single ascending SC dose of RN0361 and its metabolite AS3'N-1 in adult healthy subjects.
Urine pharmacokinetics (PK) parameters (Aet) of a single ascending SC dose of RN0361 and its metabolite AS3'N-1 in adult healthy subjects.
Urine pharmacokinetics (PK) parameters (Aeu) of a single ascending SC dose of RN0361 and its metabolite AS3'N-1 in adult healthy subjects.
Urine pharmacokinetics (PK) parameters (FE) of a single ascending SC dose of RN0361 and its metabolite AS3'N-1 in adult healthy subjects.
Absolute and percent change from baseline in APOC3 in adult healthy subjects.
Absolute and percent change from baseline in TG in adult healthy subjects.
Number and incidence of adverse events (AEs)/serious adverse events (SAEs) possibly or probably related to treatment of RN0361 in subjects with HTG.
Absolute and percent change from baseline in remnant cholesterol and VLDL-C in subjects with HTG.

Arms and interventions

RN0361Experimental

subcutaneous injections

PlaceboPlacebo comparator

calculated volume to match active treatment

Drugs: RN0361

Sites

10 sites in 2 countries

United States 6, Australia 4